Business
Gelesis Presents New Data at ObesityWeek
Gelesis Presents New Data at ObesityWeek.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0205E\n PureTech Health PLC\n 03 November 2020\n \n \n \n 3 November 2020\n PureTech Health plc\n \n \n PureTech Founded Entity Gelesis Presents Three Poster Presentations at ObesityWeek\n ®\n 2020\n \n \n New data from Gelesis show that pre-diabetes and impaired beta cell function were associated with a dysfunctional gut barrier, a potential precursor to metabolic diseases\n \n Additional analysis of Gelesis' pivotal GLOW study suggests fasting plasma glucose levels and insulin resistance could be strong predictors of weight loss with Plenity®\n \n New in-vitro beverage interaction study finds that Plenity's hydrogel maintained its properties in the presence of alcoholic or acidic drinks\n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Gelesis, today announced the release of three poster presentations at ObesityWeek 2020, the annual congress of The Obesity Society.\n \n The full text of the announcement from Gelesis is as follows:\n \n \n Gelesis Presents Three Poster Presentations at ObesityWeek\n ®\n 2020\n \n \n New data show that pre-diabetes and impaired beta cell function were associated with a dysfunctional gut barrier, a potential precursor to metabolic diseases\n \n Additional analysis of the company's pivotal GLOW study suggests fasting plasma glucose levels and insulin resistance could be strong predictors of weight loss with Plenity®\n \n New in-vitro beverage interaction study finds that Plenity's hydrogel maintained its properties in the presence of alcoholic or acidic drinks\n \n Boston, November 3, 2020 - Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat overweight, obesity and other chronic metabolic diseases, announces the release of three poster presentations at ObesityWeek® 2020, the annual congress of The Obesity Society, including:\n \n · For the first time, to the authors' knowledge, new data shows that impaired beta cell function was associated with a dysfunctional gut barrier, a potential precursor to metabolic disease;\n \n ...